Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-vfjqv Total loading time: 0 Render date: 2024-04-27T10:39:45.927Z Has data issue: false hasContentIssue false

1 - Clinical and prognostic characterization of myelodysplastic syndromes

Published online by Cambridge University Press:  22 August 2009

By
Peter L. Greenberg
Edited by
Peter L. Greenberg
Peter L. Greenberg
Affiliation:
Stanford University Cancer Center, Stanford, and VA Palo Alto Health Care System, Palo Alto, CA, USA
Peter L. Greenberg
Affiliation:
Stanford University School of Medicine, California
Get access

Summary

The myelodysplastic syndromes (MDS) provide a clinical model for evaluating the evolution of a relatively indolent malignancy into one which is frankly aggressive. The morbidity and mortality in this myeloid clonal hemopathy relate to either marrow dysfunction associated with ineffective hematopoiesis and its peripheral blood cytopenias or to disease evolution into a variant of acute myeloid leukemia (AML-MDS). MDS may arise de novo or is therapy-related (secondary, t-MDS) following treatment with chemotherapy or chemoradiotherapy for other illnesses. The disease is generally relatively indolent, with a rate of progression related to a number of defined clinical features.

Morphologic classifications

The morphologic findings in MDS consist of variable degrees of dysplasia and generally increased or normal marrow hemopoietic cellularity associated with peripheral blood cytopenias and cytopathies. There are currently two morphological classification systems used to categorize MDS patients: the initial French–American–British (FAB) and the more recently proposed World Health Organization (WHO) classification.

French–American–British

The FAB group provided a marrow-based morphologic method for systematically characterizing MDS patients. These features include assessment of the proportion of myeloblasts and degree of dysplasia in the hemopoietic cells, within at least two of the three hemopoietic cell lines. The characteristic MDS features include megaloblastoid erythropoiesis, nucleocytoplasmic asynchrony in the early myeloid and erythroid precursors, and dysmorphic megakaryocytes.

The FAB morphologic classification method separates patients into five subgroups: (1) refractory anemia (RA); (2) refractory anemia with ringed sideroblasts (RARS); (3) refractory anemia with excess blasts (RAEB); (4) refractory anemia with excess blasts in transformation (RAEB-T); and (5) chronic myelomonocytic leukemia (CMML).

Type
Chapter
Information
Myelodysplastic Syndromes
Clinical and Biological Advances
 , pp. 1 - 32
Publisher: Cambridge University Press
Print publication year: 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Greenberg, P. L. (2000). The myelodysplastic syndromes. In Hematology: Basic Principles and Practice, 3rd edn, ed. , R. B. E. Hoffman, , S. Shattil, and , H. Cohen. New York: Churchill Livingstone, pp. 1106–29Google Scholar
Bennett, J. M., Catovsky, D., Daniel, M. T.et al. (1982). Proposals for the classification of the myelodysplastic syndrome. Br. J. Haematol., 51, 189CrossRefGoogle Scholar
Groupe Français de Cytogénétique Hématologique (1991). Chronic myelomonocytic leukemia: single entity or heterogeneous disorder? A prospective multicenter study of 100 patients. Cancer Genet. Cytogenet., 55, 57CrossRef
Bennett, J. M., Catovsky, D., Daniel, M. T.et al. (1994). The chronic myeloid leukemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukemia. Br. J. Haematol., 87, 746CrossRefGoogle Scholar
Harris, N., Jaffe, E., Diebold, J.et al. (1999). WHO classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting – Airlie House, Virginia, November 1997. J. Clin. Oncol., 17, 3835–49CrossRefGoogle Scholar
Bennett, J. M. (2000). WHO classification of the acute leukemias and myelodysplastic syndrome. Int. J. Hematol., 72, 131–3Google Scholar
Brunning, R. D., Bennett, J. M., Flandrin, G. et al. (2001). Myelodysplastic syndromes. In Tumours of the Hematopoietic and Lymphoid Tissues, ed. , E. S. Jaffe, , N. L. Harris, , H. Stein, and , J. Vardiman. Lyon, France: IARC Press, pp. 62–73Google Scholar
Rosati, S., Anastasi, J., and Vardiman, J. (1996). Recurring diagnostic problems in the pathology of the myelodysplastic syndromes. Semin. Hematol., 33, 111–26Google ScholarPubMed
Katoutsi, V., Kohlmeyer, U., Maschek, H.et al. (1994). Comparison of bone marrow and hematologic findings in patients with human immunodeficiency virus infection and those with myelodysplastic syndromes and infectious disease. Am. J. Clin. Pathol., 101, 123CrossRefGoogle Scholar
Sokal, G., Michaux, J., Berghe, H.et al. (1975). A new hematological syndrome with a distinct karyotype: the 5q− chromosome. Blood, 46, 519Google Scholar
Mathew, P., Tefferi, A., Dewald, G. W.et al. (1993). The 5q− syndrome: a single institution study of 43 consecutive patients. Blood, 81, 1040Google ScholarPubMed
Larripa, I., Acevedo, S., Paulau, N. M.et al. (1991). Leukemic transformation in patients with 5q− and additional abnormalities. Haematologica, 76, 363Google ScholarPubMed
Albitar, M., Manshouri, T., Shen, Y.et al. (2002). Myelodysplastic syndrome is not merely “preleukemia”. Blood, 100, 791–8CrossRefGoogle Scholar
Greenberg, P., Anderson, J., Witte, T.et al. (2000). Problematic WHO reclassification of myelodysplastic syndromes. J. Clin. Oncol., 18, 3447–9Google ScholarPubMed
Germing, U., Gatterman, N., Strupp, C., Aivado, M., and Aul, C. (2000). Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk. Res., 24, 983–92CrossRefGoogle ScholarPubMed
Nosslinger, T., Reisner, R., Koller, E.et al. (2001). Myelodysplastic syndromes, from French–American–British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood, 98, 2935–41CrossRefGoogle ScholarPubMed
Greenberg, P. L., Bennet, J., Bloomfield, C.et al. (2003). NCCN practice guidelines for myelodysplastic syndromes, version 2004. J. Natl Comp. Cancer Network (JNCCN), 1, 456–71Google Scholar
Bowen, D., Culligan, D., Jowitt, S.et al. (2003). UK MDS guidelines group. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br. J. Haematol., 120, 187–200CrossRefGoogle ScholarPubMed
Alessandrino, E. P., Amadori, S., Barosi, G.et al.Italian Society of Hematology: evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica, 87, 1286–306
Yoshida, Y., Oguma, S., Uchino, H.et al. (1988). Refractory myelodysplastic anaemias with hypocellular bone marrow. J. Clin. Pathol., 41, 763CrossRefGoogle ScholarPubMed
Maschek, H., Kalousti, V., Rodriguez-Kaiser, M.et al. (1993). Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis. Ann. Hematol., 66, 117CrossRefGoogle ScholarPubMed
Toyama, K., Ohyashiki, K., Yoshida, Y.et al. (1993). Clinical and cytogenetic findings of myelodysplastic syndromes showing hypocellular bone marrow or minimal dysplasia, in comparison with typical myelodysplastic syndromes. Int. J. Hematol., 58, 33Google ScholarPubMed
Tichelli, A., Gratwohl, A., and Nissen, C. (1994). Late clonal complications in severe aplastic anemia. Leuk. Lymphoma, 12, 167CrossRefGoogle ScholarPubMed
Maschek, H., Georgii, A., Kaloutsi, V.et al. (1992). Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients. Eur. J. Haematol., 48, 208CrossRefGoogle ScholarPubMed
Ohyashiki, K., Sasao, I., Ohyashiki, J. H.et al. (1991). Clinical and cytogenetic characteristics of myelodysplastic syndromes developing myelofibrosis. Cancer, 68, 1783.0.CO;2-Q>CrossRefGoogle ScholarPubMed
Park, D. J. and Koeffler, H. (1996). Therapy-related myelodysplastic syndromes. Semin. Hematol., 33, 256Google ScholarPubMed
Krishnan, A., Bhatia, S., Slovak, M. L.et al. (2000). Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood, 95, 1588Google ScholarPubMed
Pedersen-Bjergaard, J., Aandersen, M., and Christiansen, D. H. (2000). Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood, 95, 3273–9Google ScholarPubMed
Beau, M. M., Albain, K., Larson, R. A.et al. (1986). Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J. Clin. Oncol., 4, 325CrossRefGoogle ScholarPubMed
Jacobs, R. H., Cornbleet, M. A., Vardiman, J.et al. (1986). Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood, 67, 1765Google ScholarPubMed
Pedersen-Bjergaard, J., Philip, P., Larsen, S. O.et al. (1990). Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute non-lymphocytic leukemia. Blood, 76, 1083Google Scholar
Pedersen-Bjergaard, J. and Philip, P. (1991). Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II. Blood, 78, 1147Google ScholarPubMed
Zhang, L., Rothman, N., Wang, Y.et al. (1996). Interphase cytogenetics of workers exposed to benzene. Environ. Health Perspect., 104, 1325–9CrossRefGoogle Scholar
Sanz, G. F., Sanz, M., Vallespi, T.et al. (1989). Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood, 74, 395–408Google Scholar
Morel, P., Hebbar, M., Lai, J.et al. (1993). Cytogenetic analysis has strong prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia, 7, 1315Google Scholar
Mufti, G. J., Stevens, J., Oscier, D. G., Hamblin, T. J., and Machin, D. (1985). Myelodysplastic syndromes: a scoring system with prognostic significance. Br. J. Haematol., 59, 425CrossRefGoogle ScholarPubMed
Aul, C., Gatterman, N., Heyll, A., and Germing, U. (1992). Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia, 6, 52Google ScholarPubMed
Toyama, K., Ohyakashi, K., Yoshida, Y., and Abe, T. (1993). Clinical implications of chromosomal abnormalities in 401 patients with MDS: a multicentric study in Japan. Leukemia, 7, 499Google ScholarPubMed
Worsley, A., Oscier, D., Stevens, J.et al. (1988). Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival. Br. J. Haematol., 68, 17CrossRefGoogle ScholarPubMed
Del Canizo, M. C., Sanz, G., San Miguel, J. F.et al. (1989). Chronic myelomonocytic leukemia clinico-biological characteristics: a multivariate analysis in a series of 70 cases. Eur. J. Haematol., 42, 466CrossRefGoogle Scholar
Stark, A. N., Thorgood, J., Head, C.et al. (1987). Prognostic factors and survival in chronic myelomonocytic leukaemia (CMML). Br. J. Cancer, 56, 59CrossRefGoogle Scholar
Lambertenghi-Deliliers, G., Orazi, A., Luksch, R.et al. (1991). Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity. Br. J. Haematol., 78, 161CrossRefGoogle ScholarPubMed
Onida, F.Kantiarjian, H., Smith, T. L.et al. (2002). Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood, 99, 840–9CrossRefGoogle ScholarPubMed
Gatto, S., Ball, G., Onida, F.et al. (2003). Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS). Blood, 102, 1622–5CrossRefGoogle Scholar
Wimazal, F., Sperr, W., Kundi, M.et al. (2001). Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. Leuk. Res., 25, 287–94CrossRefGoogle ScholarPubMed
Greenberg, P., Cox, C., Beau, M. M.et al. (1997). International scoring system (IPSS) for evaluating prognosis in myelodysplastic syndrome. Blood, 89, 2079–88Google Scholar
Berghe, H. and Michaux, L. (1997). 5q−, twenty-five years later: a synopsis. Cancer Genet. Cytogenet., 94, 1–7CrossRefGoogle ScholarPubMed
List, A. F., Kurtin, S., Glinsmann-Gibson, B.et al. (2003). Efficacy and safety of CC5013 for treatment of anemia in patients with myelodysplastic syndromes. Blood, 102, abstract 641Google Scholar
Tricot, G., Dewolf-Peeter, C., Vlietinck, R.et al. (1984). Bone marrow histology in myelodysplastic syndromes: II. Prognostic values of abnormal localization of immature precursors in MDS. Br. J. Haematol., 58, 217CrossRefGoogle Scholar
Tricot, G., Vlietinck, R., Boogaerts, M. A.et al. (1985). Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis. Br. J. Haematol., 60, 19CrossRefGoogle ScholarPubMed
Greenberg, P. L. (1996). Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes. Semin. Hematol., 33, 163–75Google ScholarPubMed
Berthier, R., Douday, F., Metral, J.et al. (1979). In vitro granulopoiesis in oligoblastic leukemia: prognostic value, characterization, and serial cloning of bone marrow colony and cluster forming cells in agar culture. Biomedicine, 30, 305Google ScholarPubMed
Greenberg, P. L., Bax, I., Mara, B.et al. (1976). The myeloproliferative disorders: correlation between clinical evolution and alteration of granulopoiesis. Am. J. Med., 61, 878CrossRefGoogle Scholar
Faille, A., Dresch, C., Poirer, O.et al. (1978). Prognostic value of in vitro bone marrow culture in refractory anaemia with excess of myeloblasts. Scand. J. Haematol., 20, 280CrossRefGoogle ScholarPubMed
Milner, G. R., Testa, N., Geary, C. G.et al. (1977). Bone marrow studies in refractory cytopenia and smoldering leukaemia. Br. J. Haematol., 35, 251CrossRefGoogle Scholar
Spitzer, G., Verma, D., Dicke, K.et al. (1979). Subgroups of oligoleukemia as identified by in vitro agar culture. Leuk. Res., 3, 29CrossRefGoogle ScholarPubMed
Verma, D. S., Spitzer, G., Dicke, K. A.et al. (1979). In vitro agar culture patterns in preleukemia and their clinical significance. Leuk. Res., 3, 41CrossRefGoogle ScholarPubMed
Greenberg, P., Cox, C., and Bennett, J. (1997). IPSS and other prognostic scoring systems for MDS. Blood, 90, 4232–4Google Scholar
Pierre, R. V., Catovsky, D., Mufti, G. J.et al. (1989). Clinical-cytogenetic correlations in myelodysplasia (preleukemia). Cancer Genet. Cytogenet., 40, 149CrossRefGoogle Scholar
Yunis, J. J., Lobell, M., Arnesen, M. A.et al. (1988). Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia. Br. J. Haematol., 68, 189CrossRefGoogle ScholarPubMed
Greenberg, P., Beau, M., Fenaux, P.et al. (1997). Application of the International Prognostic Scoring System for MDS. Blood, 90, 2843–6Google Scholar
Pfeilstocker, M., Reisner, R., Nosslinger, T.et al. (1999). Cross-validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics. Br. J. Haematol., 106, 455–63CrossRefGoogle ScholarPubMed
Verburgh, E., Achten, R., Maes, B.et al. (2003). Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes. J. Clin. Oncol., 21, 273–82CrossRefGoogle ScholarPubMed
Zhao, W. L., Xu, L., Wu, W.et al. (2002). The myelodysplastic syndromes: analysis of prognostic factors and comparison of prognostic systems in 128 Chinese patients from a single institution. Hematol. J., 3, 137–44CrossRefGoogle ScholarPubMed
Lee, J. H., Lee, J., Shin, Y. R.et al. (2003). Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia, 17, 305–13CrossRefGoogle ScholarPubMed
Cermak, J., Vitek, A., and Michalova, K. (2004). Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation. Leuk. Res., 28, 551–7CrossRefGoogle Scholar
Nevill, T. J., Fung, H., Shepherd, J. D.et al. (1998). Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood, 92, 1910–17Google ScholarPubMed
Appelbaum, F. R. and Anderson, J. (1998). Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia, 12 (suppl. 1), S25–9Google ScholarPubMed
Sole, F., Epsinet, B., Sanz, G. F.et al. (2000). Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Español de Citogenética Hematológica. Br. J. Haematol., 108, 346–56CrossRefGoogle ScholarPubMed
Maes, B., Meeus, P., Michaux, L.et al. (1999). Application of the International Prognostic Scoring System for myelodysplastic syndromes. Ann. Oncol., 10, 825–9CrossRefGoogle ScholarPubMed
Lambertenghi Deliliers, G., Annaloro, C., Soligo, D., and Oriani, A. (1998). The diagnostic and prognostic value of bone marrow immunostaining in myelodysplastic syndromes. Leuk. Lymphoma, 28, 231–9CrossRefGoogle ScholarPubMed
Bellamy, W. T., Richter, L., Sirjani, D.et al. (2001). Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood, 97, 1427–34CrossRefGoogle ScholarPubMed
Pruneri, G., Bertolini, F., Soligo, D.et al. (1999). Angiogenesis in myelodysplastic syndromes. Br. J. Cancer, 81, 1398–401CrossRefGoogle ScholarPubMed
Aguayo, A., Kantarjian, H., Manshouri, T.et al. (2000). Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood, 96, 2240–5Google ScholarPubMed
Ogata, T., Nakamura, K., Yokose, N.et al. (2002). Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood, 100, 3887–96CrossRefGoogle ScholarPubMed
Wells, D. A., Benesch, M., Loken, M. R.et al. (2003). Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood, 102, 394–403CrossRefGoogle ScholarPubMed
Dunn, D. E., Tanattanacharoen, P., Boccuni, P.et al. (1999). Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann. Intern. Med., 131, 401–8CrossRefGoogle ScholarPubMed
Saunthararajah, Y., Nakamura, R., Nam, J. M.et al. (2002). HLA-DR15 (DR2) is over-represented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood, 100, 1570–4Google Scholar
Maciejewski, J. P., Follman, D., Nakamura, R.et al. (2001). Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood, 98, 3513–19CrossRefGoogle ScholarPubMed
Padua, R. A., Guinn, B., Al-Sabah, A. I.et al. (1998). RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia, 12, 887–92CrossRefGoogle ScholarPubMed
Shih, L. Y., Huang, C., Wang, P. N.et al. (2004). Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia, 18, 466–75CrossRefGoogle ScholarPubMed
Paquette, R. L., Landaw, E., Pierre, R. V.et al. (1993). N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood, 82, 590–9Google ScholarPubMed
Neubauer, A., Greenberg, P., Negrin, R.et al. (1994). Mutations in the ras proto-oncogenes in patients with myelodysplastic syndromes. Leukemia, 8, 638Google ScholarPubMed
Ridge, S. A., Worwood, M., Oscier, D.et al. (1990). FMS mutations in myelodysplastic, leukemic, and normal subjects. Proc. Natl Acad. Sci. U.S.A., 87, 1377CrossRefGoogle ScholarPubMed
Tobal, K., Pagliuca, A., Bhatt, B.et al. (1990). Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia. Leukemia, 4, 486
Fidler, C., Watkins, F., Bowen, D. T.et al. (2004). N-Ras, Flt3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q). Haematologica, 89, 865–6Google Scholar
Sugimoto, K., Hirano, N., Toyoshima, H.et al.Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood, 81, 3022
Adamson, D. J., Dawson, A., Bennett, B.et al. (1995). p53 mutation in the myelodysplastic syndromes. Br. J. Haematol., 89, 61CrossRefGoogle ScholarPubMed
Horiike, S., Kita-Sasai, Y., Nakao, M., and Taniwaki, M. (2003). Configuration of the TP53 gene as an independent prognostic parameter of myelodysplastic syndrome. Leuk. Lymphoma, 44, 915–22CrossRefGoogle ScholarPubMed
Tang, J. L., Tien, H., Lin, M. T.et al. (1998). p53 mutation in advanced stage of primary myelodysplastic syndrome. Anticancer Res., 18, 3757Google ScholarPubMed
Mori, N., Hidai, H., Yokota, J.et al. (1995). Mutations of the p53 gene in myelodysplastic syndrome and overt leukemia. Leuk. Res., 19, 869CrossRefGoogle ScholarPubMed
Horiike, S., Misawa, S., Kaneko, H.et al. (1999). Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of nos 5 and/or 7 and its possible relationship to replication error phenotype. Leukemia, 13, 1235CrossRefGoogle ScholarPubMed
Wattel, E., Preudhomme, C., Hecquet, B.et al. (1994). p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood, 84, 3148Google ScholarPubMed
Ben-Yehuda, D., Krichevsky, S., Caspi, O.et al. (1996). Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood, 88, 4296Google ScholarPubMed
Kita-Sasai, Y., Horiike, S., Misawa, S.et al. (2001). International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome. Br. J. Haematol., 115, 309–12CrossRefGoogle ScholarPubMed
Lai, J. L., Preudhomme, C., Zandecki, M.et al. (1995). Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of p53 mutations. Leukemia, 9, 370Google Scholar
Cilloni, D., Gottardi, E., Messa, F.et al. (2003). Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J. Clin. Oncol., 21, 1988–95CrossRefGoogle ScholarPubMed
Boudard, D., Vasselon, C., Bertheas, M. F.et al. (2002). Expression and prognostic significance of Bcl-2 family proteins in myelodysplastic syndromes. Am. J. Hematol., 70, 115–25CrossRefGoogle ScholarPubMed
Rajapaksa, R., Ginzton, N., Rott, L. (1996). Altered oncogene expression and apoptosis in myelodysplastic syndrome marrow cells. Blood, 88, 4275–87Google ScholarPubMed
Parker, J. E., Mufti, G., Rasool, F.et al. (2000). The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood, 96, 3932–8Google ScholarPubMed
Davis, R. E. and Greenberg, P. L. (1998). Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: impact on disease progression. Leuk. Res., 22, 767–77CrossRefGoogle Scholar
Quesnel, B., Guillerm, G., Vereecque, R.et al. (1998). Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood, 91, 2985–90Google ScholarPubMed
Nakao, M., Horiike, S., Fukushima-Nakase, Y.et al. (2004). Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome. Br. J. Haematol., 125, 709–19CrossRefGoogle ScholarPubMed
Harada, H., Harada, Y., Niimi, H.et al. (2004). High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood, 103, 2316–24CrossRefGoogle ScholarPubMed
Shih, L. Y., Lin, T., Wang, P. N.et al. (2004). Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome. Cancer, 101, 989–98CrossRefGoogle ScholarPubMed
Ohyashiki, J. H., Iwama, H., Yahata, N.et al. (1999). Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. Clin. Cancer Res., 5, 1155–60Google ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×